Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q4998035> ?p ?o }
Showing triples 1 to 37 of
37
with 100 triples per page.
- Q4998035 subject Q19620748.
- Q4998035 subject Q8256381.
- Q4998035 subject Q8343736.
- Q4998035 subject Q8679151.
- Q4998035 subject Q8758634.
- Q4998035 subject Q8879081.
- Q4998035 subject Q8918235.
- Q4998035 subject Q9516482.
- Q4998035 subject Q9536267.
- Q4998035 abstract "Bupropion/zonisamide (planned trade name Empatic) is an experimental drug combination for the treatment of obesity.It is being developed by Orexigen Therapeutics. It is currently at phase II testing. The combination consists of two prescription medications approved by the U.S. Food and Drug Administration (FDA) for other ailments. When mixed together and tested along with proper diet and moderate exercise, they produced a substantial weight loss effect higher than the group taking a placebo. Empatic was called Excalia before its name was changed.".
- Q4998035 thumbnail Bupropion_and_zonisamide.svg?width=300.
- Q4998035 wikiPageWikiLink Q12174.
- Q4998035 wikiPageWikiLink Q18158260.
- Q4998035 wikiPageWikiLink Q19620748.
- Q4998035 wikiPageWikiLink Q204711.
- Q4998035 wikiPageWikiLink Q410943.
- Q4998035 wikiPageWikiLink Q411398.
- Q4998035 wikiPageWikiLink Q412256.
- Q4998035 wikiPageWikiLink Q4998036.
- Q4998035 wikiPageWikiLink Q576618.
- Q4998035 wikiPageWikiLink Q8256381.
- Q4998035 wikiPageWikiLink Q8343736.
- Q4998035 wikiPageWikiLink Q8679151.
- Q4998035 wikiPageWikiLink Q8758634.
- Q4998035 wikiPageWikiLink Q8879081.
- Q4998035 wikiPageWikiLink Q8918235.
- Q4998035 wikiPageWikiLink Q9516482.
- Q4998035 wikiPageWikiLink Q9536267.
- Q4998035 wikiPageWikiLink Q961634.
- Q4998035 type ChemicalSubstance.
- Q4998035 type Drug.
- Q4998035 type ChemicalObject.
- Q4998035 type Thing.
- Q4998035 type Q8386.
- Q4998035 comment "Bupropion/zonisamide (planned trade name Empatic) is an experimental drug combination for the treatment of obesity.It is being developed by Orexigen Therapeutics. It is currently at phase II testing. The combination consists of two prescription medications approved by the U.S. Food and Drug Administration (FDA) for other ailments. When mixed together and tested along with proper diet and moderate exercise, they produced a substantial weight loss effect higher than the group taking a placebo.".
- Q4998035 label "Bupropion/zonisamide".
- Q4998035 depiction Bupropion_and_zonisamide.svg.